286 related articles for article (PubMed ID: 32472498)
1. Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.
Feroze RA; Leya J; Herron T; Hayek SS
J Cardiovasc Transl Res; 2020 Jun; 13(3):417-430. PubMed ID: 32472498
[TBL] [Abstract][Full Text] [Related]
2. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Imaging in Cardio-oncology.
Tong D; Zaha VG
J Cardiovasc Transl Res; 2020 Jun; 13(3):357-366. PubMed ID: 31696405
[TBL] [Abstract][Full Text] [Related]
4. Imaging in Cardio-Oncology: Where Are We and Where Should We Be Going?
Steingart RM; Chandrashekhar Y; Marwick TH
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1209-1211. PubMed ID: 30092977
[No Abstract] [Full Text] [Related]
5. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
6. Induced pluripotent stem cells in cardiovascular drug discovery.
Mercola M; Colas A; Willems E
Circ Res; 2013 Feb; 112(3):534-48. PubMed ID: 23371902
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors.
Izumi-Nakaseko H; Fujiyoshi M; Hagiwara-Nagasawa M; Goto A; Chiba K; Kambayashi R; Naito AT; Ando K; Kanda Y; Ishii I; Sugiyama A
Cardiovasc Toxicol; 2020 Feb; 20(1):58-70. PubMed ID: 31280457
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
Liu S; Fang C; Zhong C; Li J; Xiao Q
Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
[TBL] [Abstract][Full Text] [Related]
10. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.
Mordwinkin NM; Burridge PW; Wu JC
J Cardiovasc Transl Res; 2013 Feb; 6(1):22-30. PubMed ID: 23229562
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology.
Pepe A; Pizzino F; Gargiulo P; Perrone-Filardi P; Cadeddu C; Mele D; Monte I; Novo G; Zito C; Di Bella G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S45-54. PubMed ID: 27183525
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
13. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology.
Nair P; Prado M; Perea-Gil I; Karakikes I
Stem Cells Transl Med; 2019 Aug; 8(8):758-767. PubMed ID: 31020786
[TBL] [Abstract][Full Text] [Related]
14. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
15. Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity.
Quatromoni N; Scherrer-Crosbie M
Curr Cardiol Rep; 2018 Jun; 20(8):67. PubMed ID: 29931487
[TBL] [Abstract][Full Text] [Related]
16. Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.
Gintant G; Burridge P; Gepstein L; Harding S; Herron T; Hong C; Jalife J; Wu JC
Circ Res; 2019 Oct; 125(10):e75-e92. PubMed ID: 31533542
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
18. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH
Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050
[TBL] [Abstract][Full Text] [Related]
19. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
[TBL] [Abstract][Full Text] [Related]
20. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient.
Plana JC; Thavendiranathan P; Bucciarelli-Ducci C; Lancellotti P
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1173-1186. PubMed ID: 30092972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
